Des analgésiques, des thérapies physiques et des traitements ciblés peuvent aider.
Douleurs osseusesTraitementsTumeurs prostatiques
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
L'âge, les antécédents familiaux et l'origine ethnique sont des facteurs de risque connus.
Facteurs de risqueTumeurs prostatiquesAntécédents familiaux
#2
L'alimentation influence-t-elle le risque ?
Oui, une alimentation riche en graisses animales peut augmenter le risque de cancer de la prostate.
AlimentationFacteurs de risqueTumeurs prostatiques
#3
Le surpoids est-il un facteur de risque ?
Oui, l'obésité est associée à un risque accru de développer des tumeurs prostatiques.
ObésitéFacteurs de risqueTumeurs prostatiques
#4
Le tabagisme joue-t-il un rôle ?
Oui, le tabagisme est lié à un risque accru de plusieurs cancers, y compris celui de la prostate.
TabagismeFacteurs de risqueTumeurs prostatiques
#5
Les antécédents médicaux influencent-ils le risque ?
Oui, des antécédents de maladies prostatiques augmentent le risque de cancer de la prostate.
Antécédents médicauxFacteurs de risqueTumeurs prostatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs prostatiques résistantes à la castration : Questions médicales les plus fréquentes",
"headline": "Tumeurs prostatiques résistantes à la castration : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs prostatiques résistantes à la castration : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs prostatiques résistantes à la castration"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de la prostate",
"url": "https://questionsmedicales.fr/mesh/D011471",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de la prostate",
"code": {
"@type": "MedicalCode",
"code": "D011471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C12.900.619.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs prostatiques résistantes à la castration",
"alternateName": "Prostatic Neoplasms, Castration-Resistant",
"code": {
"@type": "MedicalCode",
"code": "D064129",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Karim Fizazi",
"url": "https://questionsmedicales.fr/author/Karim%20Fizazi",
"affiliation": {
"@type": "Organization",
"name": "Institut Gustave Roussy and University of Paris Sud, Villejuif, France."
}
},
{
"@type": "Person",
"name": "Neal Shore",
"url": "https://questionsmedicales.fr/author/Neal%20Shore",
"affiliation": {
"@type": "Organization",
"name": "Carolina Urologic Research Center and Atlantic Urology Clinics, Myrtle Beach, SC, USA."
}
},
{
"@type": "Person",
"name": "Joaquin Mateo",
"url": "https://questionsmedicales.fr/author/Joaquin%20Mateo",
"affiliation": {
"@type": "Organization",
"name": "Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Fred Saad",
"url": "https://questionsmedicales.fr/author/Fred%20Saad",
"affiliation": {
"@type": "Organization",
"name": "From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.)."
}
},
{
"@type": "Person",
"name": "Johann S de Bono",
"url": "https://questionsmedicales.fr/author/Johann%20S%20de%20Bono",
"affiliation": {
"@type": "Organization",
"name": "The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address: johann.de-bono@icr.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Steroidogenesis in castration-resistant prostate cancer.",
"datePublished": "2022-11-11",
"url": "https://questionsmedicales.fr/article/36376200",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.urolonc.2022.10.018"
}
},
{
"@type": "ScholarlyArticle",
"name": "Molecular Mechanisms of Castrate-Resistant Prostate Cancer.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36309418",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ucl.2022.07.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.",
"datePublished": "2022-11-18",
"url": "https://questionsmedicales.fr/article/36401126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41391-022-00618-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Current therapy and drug resistance in metastatic castration-resistant prostate cancer.",
"datePublished": "2023-04-14",
"url": "https://questionsmedicales.fr/article/37068396",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drup.2023.100962"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Molecular signatures in castration-resistant prostate cancers: An update].",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35871861",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bulcan.2022.06.007"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies urogénitales",
"item": "https://questionsmedicales.fr/mesh/D000091642"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil urogénital",
"item": "https://questionsmedicales.fr/mesh/D014565"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de l'appareil génital mâle",
"item": "https://questionsmedicales.fr/mesh/D005834"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs de la prostate",
"item": "https://questionsmedicales.fr/mesh/D011471"
},
{
"@type": "ListItem",
"position": 6,
"name": "Tumeurs prostatiques résistantes à la castration",
"item": "https://questionsmedicales.fr/mesh/D064129"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs prostatiques résistantes à la castration - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs prostatiques résistantes à la castration",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs prostatiques résistantes à la castration",
"description": "Comment diagnostiquer une tumeur prostatique résistante ?\nQuels tests sanguins sont utilisés ?\nQuand suspecter une résistance à la castration ?\nQuel rôle joue l'imagerie dans le diagnostic ?\nQuels symptômes peuvent indiquer une progression ?",
"url": "https://questionsmedicales.fr/mesh/D064129#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs prostatiques résistantes à la castration",
"description": "Quels sont les symptômes courants ?\nComment la douleur se manifeste-t-elle ?\nY a-t-il des symptômes systémiques ?\nLes troubles urinaires sont-ils fréquents ?\nComment la fatigue se manifeste-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D064129#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs prostatiques résistantes à la castration",
"description": "Peut-on prévenir les tumeurs prostatiques ?\nQuel rôle joue l'alimentation ?\nL'exercice physique aide-t-il ?\nLes dépistages réguliers sont-ils importants ?\nLe tabagisme influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064129#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs prostatiques résistantes à la castration",
"description": "Quels traitements sont disponibles ?\nComment fonctionne l'hormonothérapie ?\nLa chimiothérapie est-elle efficace ?\nQuelles sont les thérapies ciblées ?\nY a-t-il des traitements expérimentaux ?",
"url": "https://questionsmedicales.fr/mesh/D064129#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs prostatiques résistantes à la castration",
"description": "Quelles complications peuvent survenir ?\nComment les métastases affectent-elles la santé ?\nY a-t-il des complications liées aux traitements ?\nLes complications psychologiques sont-elles fréquentes ?\nComment gérer les douleurs osseuses ?",
"url": "https://questionsmedicales.fr/mesh/D064129#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs prostatiques résistantes à la castration",
"description": "Quels sont les principaux facteurs de risque ?\nL'alimentation influence-t-elle le risque ?\nLe surpoids est-il un facteur de risque ?\nLe tabagisme joue-t-il un rôle ?\nLes antécédents médicaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064129#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur prostatique résistante ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des tests sanguins, des biopsies et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dosage de l'antigène prostatique spécifique (APS) est essentiel pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quand suspecter une résistance à la castration ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une progression de la maladie malgré un traitement hormonal indique une résistance."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie permet de visualiser l'étendue de la maladie et d'évaluer les métastases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une progression ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs osseuses, des difficultés urinaires et une perte de poids peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs pelviennes, troubles urinaires et fatigue."
}
},
{
"@type": "Question",
"name": "Comment la douleur se manifeste-t-elle ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur peut être localisée dans le bas du dos, les hanches ou les cuisses."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fièvre, la perte d'appétit et la perte de poids peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les troubles urinaires sont-ils fréquents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés à uriner, des envies fréquentes ou des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment la fatigue se manifeste-t-elle ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fatigue peut être persistante et affecter les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs prostatiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode garantie, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en fruits, légumes et oméga-3 peut être bénéfique."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé globale et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies prostatiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers, y compris la prostate."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, l'hormonothérapie et les thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Comment fonctionne l'hormonothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle vise à réduire les niveaux de testostérone pour ralentir la progression tumorale."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la taille des tumeurs et soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles sont les thérapies ciblées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles visent des anomalies spécifiques des cellules tumorales pour inhiber leur croissance."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques testent de nouvelles approches, comme l'immunothérapie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des douleurs osseuses, des fractures et des problèmes urinaires."
}
},
{
"@type": "Question",
"name": "Comment les métastases affectent-elles la santé ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les métastases peuvent causer des douleurs, des fractures et affecter les organes vitaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées aux traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme la fatigue, des nausées et des troubles hormonaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications psychologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'anxiété et la dépression peuvent être des complications courantes chez les patients."
}
},
{
"@type": "Question",
"name": "Comment gérer les douleurs osseuses ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analgésiques, des thérapies physiques et des traitements ciblés peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les antécédents familiaux et l'origine ethnique sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses animales peut augmenter le risque de cancer de la prostate."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à un risque accru de développer des tumeurs prostatiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme joue-t-il un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est lié à un risque accru de plusieurs cancers, y compris celui de la prostate."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies prostatiques augmentent le risque de cancer de la prostate."
}
}
]
}
]
}
From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).
Publications dans "Tumeurs prostatiques résistantes à la castration" :
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Publications dans "Tumeurs prostatiques résistantes à la castration" :
From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).
Publications dans "Tumeurs prostatiques résistantes à la castration" :
From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).
Publications dans "Tumeurs prostatiques résistantes à la castration" :
From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).
Publications dans "Tumeurs prostatiques résistantes à la castration" :
From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).
Publications dans "Tumeurs prostatiques résistantes à la castration" :
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome th...
Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-recep...
Genetic profiling of patients with prostate cancer could potentially identify mutations prone to castration-resistant prostate cancer (CRPC). Here, we aimed to identify the differences in genetic prof...
A total of 103 samples were collected, including 62 DNA samples from the tumor tissues of 59 HSPC patients and 41 cell-free DNA (cfDNA) samples from prostate cancer patients at different cancer stages...
By comparing to that of cfDNA sequencing, the results from DNA sequencing of 1-needle (80%) and mixed 12-needle (77.8%) biopsies are highly comparable. FOXA1 (30.5%), CDK12 (23.7%), and TP53 (22.0%) w...
In this study, we demonstrated that the cfDNA can be used in genetic profiling in prostate cancer and our newly established panel is capable of predicting which mHSPC patient has a high risk of early ...
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among m...
Castration resistant prostate cancers are highly heterogenous at the molecular level. With the use of new generation sequencing technologies, a series of alterations were identified, opening the way f...
Prostate cancer (PCa) is the second leading cause of cancer-related death in American men. PCa that relapses after hormonal therapies, referred to as castration resistant PCa (CRPC), often presents wi...
Enzalutamide (Enz) is a next-generation androgen receptor (AR) antagonist used to treat castration-resistant prostate cancer (CRPC). Unfortunately, the relapsing nature of CRPC results in the developm...
The natural history of prostate cancer (PC) almost always evolves to castration-resistant prostate cancer (CRPC) status, sometimes comprising pure or mixed neuroendocrine prostate cancers (NEPC) diffe...
This review was based on three recent meta-analysis concerning CgA and prostate cancer. Further data were obtained from PubMed and Embase databases by searches using keywords, including chromogranin A...
CgA levels remain largely unchanged during the early PC evolution. The development of NEPC is characterised by lower PSA secretion and increased CgA secretion. Data supporting the prognostic value of ...
CgA monitoring at baseline and regularly during mCRPC management may be useful for monitoring disease evolution. An increased CgA baseline levels and increasing CgA levels may assist physicians with c...
Neuroendocrine prostate cancer (NEPC) is a multi-resistant variant of prostate cancer (PCa) that frequently emerges in castration-resistant prostate cancer (CRPC). NEPC is usually associated with tumo...
Metastasis to bone is the leading cause of death from prostate cancer. Interaction between tumor cells and bone cells can promote progression and influence tumor phenotype. It is known that prostate c...